Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | NAAA | Q02083 | 3/20 | 0.44 |
| ▸ | IL6ST | P40189 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 8/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205626 | 1.00 | PPARA (0.44) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL7066044 | 1.00 | PPARA (0.44) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL4205621 | 1.00 | PPARA (0.44) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL4204054 | 0.91 | PPARA (0.45) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL4204056 | 0.91 | PPARA (0.45) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL4204060 | 0.91 | PPARA (0.45) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL7034652 | 0.89 | NAAA (0.45) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL7034658 | 0.89 | NAAA (0.45) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL1049822 | 0.89 | NAAA (0.46) | PPARANAAAIL6STIDH1FAAH | |
| SCHEMBL2029159 | 0.89 | NAAA (0.46) | PPARANAAAIL6STIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846903-B2 | Acyl-urea derivatives and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-09-30 | — | — | US | disclosed |
| US-20100280124-A1 | ACYL-UREA DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-11-04 | — | — | US | disclosed |
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247743-A1 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | SCN2A, SCN1A, ORAI2 | PPARA 2465/4885NAAA 1958/4885IL6ST 867/4885 |
| US-20100280124-A1 | ACYL-UREA DERIVATIVES AND USES THEREOF | ABAT, HDAC6, ACAT1 | PPARA 604/4885NAAA 4/4885IL6ST 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.